Literature DB >> 32530147

[Standard procedures in dialysis during the Covid-19 epidemic].

Michela Ippolito1, Giovannni Battista Di Tria1, Cinzia Aldrigo1, Mariangela Ricci1, Ulisse Zoni1, Antonino Giordano1, Mario Cozzolino2.   

Abstract

Scope: The aim of this document has been to define standard procedures for dealing with dialysis patients once the first cases of novel Coronavirus 2019-nCoV (Covid-19) were confirmed among the Italian population. Applicability: These procedures, that refer exclusively to the hospital's dialysis rooms, are currently implemented at the ASST Santi Paolo e Carlo in Milan and two smaller centers in the Milan area. Description: We describe the preemptive measures adopted by the staff at our dialysis unit since 24/02/2020, in order to slow down the transmission of Covid-19. They have allowed us to adopt a uniform approach towards all patients, streamlining the way we identify and deal with suspected, likely and confirmed Coronavirus infections. To start with, all patients coming to the hospital for their dialytic session have been treated as potentially infectious and everybody has been following closely the standard protocols regarding personal protective equipment (PPE). Copyright by Società Italiana di Nefrologia SIN, Rome, Italy.

Entities:  

Keywords:  Covid-19; dialysis; personal protective equipment; prevention

Mesh:

Year:  2020        PMID: 32530147

Source DB:  PubMed          Journal:  G Ital Nefrol        ISSN: 0393-5590


  2 in total

Review 1.  The frail world of haemodialysis patients in the COVID-19 pandemic era: a systematic scoping review.

Authors:  Gaetano Alfano; Annachiara Ferrari; Riccardo Magistroni; Francesco Fontana; Gianni Cappelli; Carlo Basile
Journal:  J Nephrol       Date:  2021-08-21       Impact factor: 3.902

2.  COVID-19 in a dialysis center in Milan from March to June 2020: understanding how to respond to the second wave of the pandemic.

Authors:  Andrea Galassi; Lorenza Magagnoli; Mario Cozzolino
Journal:  J Nephrol       Date:  2021-02       Impact factor: 4.393

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.